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Background: Realizing the therapeutic benefits of quercetin is mostly hampered by its low 
water solubility and poor absorption. In light of the advantages of nanovehicles in the delivery 
of flavanoids, we aimed to deliver quercetin perorally with nanomicelles made from the diblock 
copolymer, polyethylene glycol (PEG)-derivatized phosphatidylethanolamine (PE).
Methods: Quercetin-loaded nanomicelles were prepared by using the film casting method, 
and were evaluated in terms of drug incorporation efficiency, micelle size, interaction with 
Caco-2 cells, and anticancer activity in the A549 lung cancer cell line and murine xenograft 
model.
Results: The incorporation efficiency into the nanomicelles was $88.9% when the content of 
quercetin was up to 4% w/w, with sizes of 15.4–18.5 nm and polydispersity indices of ,0.250. 
Solubilization of quercetin by the nanomicelles increased its aqueous concentration by 110-fold. 
The quercetin nanomicelles were stable when tested in simulated gastric (pH 1.2) and intestinal 
(pH 7.4) fluids, and were non-toxic to the Caco-2 cells as reflected by reversible reduction in 
transepithelial electrical resistance and #25% lactose dehydrogenase release. The anticancer 
activity of quercetin could be significantly improved over the free drug through the   nanomicellar 
formulation when tested using the A549 cancer cell line and murine xenograft model. The 
nanomicellar quercetin formulation was well tolerated by the tumor-bearing animals, with no 
significant weight loss observed at the end of the 10-week study period.
Conclusion: A stable PEG-PE nanomicellar formulation of quercetin was developed with 
enhanced peroral anticancer activity and no apparent toxicity to the intestinal epithelium.
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Introduction
Cancer is a public health problem that affects many countries in the world. Globally, 
lung cancer is the leading cause of cancer death. In the treatment of advanced lung 
cancer, chemotherapy remains the mainstay; however, only modest increase in survival 
has been observed at the cost of significant toxicity to patients.1 It is imperative to search 
for new therapeutics with improved efficacy and safety profiles. In the anticancer drug 
discovery and development process, compounds with the highest anticancer activities 
often have bulky hydrophobic groups within their chemical structures, rendering them 
water-insoluble.2 Low water solubility not only gives rise to formulation difficulties but 
also serious therapeutic challenges. Administering the poorly soluble drug candidate 
intravenously might result in serious complications such as embolism and respiratory 
system failure due to drug precipitation,3 whereas poor absorption would result from 
extravascular dosing.4
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The family of flavonoid compounds is one such 
  example which has been shown to be promising for the 
wide   applicability in the prevention and therapy of cancer, 
neurodegenerative, and cardiovascular diseases. Yet, the 
major hurdle in their clinical usage is poor water solubility, 
thus affecting their peroral biological activity.5 Among this 
family of agents, quercetin has been studied extensively for 
its anticancer   activity, whereby it could inhibit a number of 
signal transduction targets important to cancer cell survival, 
proliferation, and metastasis.6,7 Quercetin progressed to 
early-stage clinical trials as an anticancer agent more than a 
decade ago; nevertheless, its administration required the use 
of solvents such as dimethylsulfoxide or ethanol.8   Chemical 
modifications have been attempted to improve quercetin 
solubility but could result in a loss of drug potency.9 Thus, 
alternative strategies based on the use of nanotechnologies 
have been undertaken to improve the water solubility and/or 
the bioavailability of quercetin so as to improve its   biological 
activity.5 While most of the nanovehicles are designed with 
compositions sufficiently stable for   intravenous adminis-
tration, which is the most conventional route for cancer 
chemotherapy, orally active cancer chemotherapeutics 
have emerged as an attractive treatment modality because 
of patient preference, convenience in administration, and 
applicability in outpatient setting.10 A few studies have 
shown promising peroral antioxidant activity of quercetin 
when it was delivered by nanoscaled delivery systems,11,12 
and recently, a lipid-based, submicron (∼400 nm) vesicular 
complex of quercetin has been developed with improved 
peroral anticancer activity as compared to a peroral quercetin 
suspension.13
In light of the advantages of peroral anticancer drug 
delivery and recent developments in the use of nanovehicles 
for the delivery of flavonoids,5 we have attempted to deliver 
quercetin perorally through the use of polyethylene glycol 
(PEG)-derivatized phosphatidylethanolamine (PE) as the 
diblock copolymer to form a self-assembled nanomicellar 
delivery system, and have compared the anticancer activity 
of this nanomicellar formulation with a peroral suspen-
sion of quercetin. The research on PEG-PE nanomicellar 
systems, pioneered by Torchilin and Alkan-Onyuksel,14–16 
has contributed greatly to the intravenous delivery of 
water-insoluble agents. For instance, improved therapeu-
tic efficacy of the intravenously administered PEG-lipid 
micelle formulation of paclitaxel has been demonstrated in 
tumor-bearing mice.15,16 The potential of PEG-lipid nano-
micelles for the peroral administration of water-insoluble 
compounds has yet to be demonstrated in animal models. 
Here, we have shown that the peroral anticancer activity of 
quercetin could be significantly increased when delivered 
in PEG-PE nanomicellar systems in the A549 human lung 
tumor xenograft model.
Materials and methods
Materials
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000] (DSPE-PEG2000) 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[poly(ethyleneglycol)-2000-N′-carboxyfluorescein] (FITC-
DSPE-PEG2000) were purchased from Avanti-Polar-Lipids 
(Alabaster, AL). Cell culture media and supplements were 
from Gibco (Grand Island, NY). All other chemicals were 
purchased from Sigma-Aldrich Inc (St Louis, MO). A549, 
MDA-MB-231, and Caco-2 cell lines were purchased from 
the American Type Culture Collection (Manassas, VA).
Preparation of nanomicellar quercetin
The quercetin nanomicelles were prepared as follows: briefly, 
DSPE-PEG2000 was dissolved in chloroform and quercetin 
in ethanol, the two organic solutions were mixed together 
according to the various weight proportions of drug and 
PEG-lipid. Subsequently, the organic phase was evaporated 
off under a stream of nitrogen gas to obtain a dried thin film. 
The film was further placed under vacuum for at least 3 hours 
to remove the residual solvent. Hank’s balanced salt solution 
or phosphate-buffered saline (PBS) was used to hydrate 
the thin film to form the nanomicelles. For fluorescence-
labeled nanomicelles, 1% of FITC-DSPE-PEG2000 was 
mixed with 99% of DSPE-PEG2000 (by mole) in chloroform, 
  followed by evaporation and hydration as described above. 
  Unincorporated quercetin was removed by centrifugation at 
13,000 rpm for 10 minutes followed by filtration through a 
0.2-µm filter. The resultant nanomicelle samples were frozen 
at −86°C for 8 hours (ULT Freezer; Thermo Electron Corpo-
ration Forma, Waltham, MA,) and subsequently lyophilized 
at −50°C to −55°C for 48 hours at 5 Pa (Alpha 2–4 LDplus 
Freeze Dryer; Christ, Osterode, Germany). No secondary 
drying was performed. Lyophilized samples were stored at 
4°C ± 2°C until further evaluation, and subsequently were 
reconstituted to original volume using milli-Q water as and 
when required. Drug concentration was determined by read-
ing absorbance at 376 nm after mixing the micelle samples 
in ethanol, using a standard curve constructed with querce-
tin dissolved in ethanol. The size of the nanomicelles was 
determined by dynamic light scattering (Malvern   Zetasizer 
3000HS; Malvern, Worcestershire, UK).
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Stability of nanomicellar quercetin  
in simulated physiological fluids
The stability of quercetin nanomicelles were evaluated using 
two different aqueous media. The composition of the simu-
lated gastric fluid (SGF) was as follows: 0.2% w/v NaCl in 
0.7% v/v HCl, pH 1.2, and that of the simulated intestinal 
fluid (SIF) was as follows: 0.05 M potassium dihydrogen 
phosphate/0.02 M sodium hydroxide, pH 7.0. The nanomi-
cellar quercetin formulation was dialyzed in 1:5000 v/v in 
the respective simulated fluids for the specified duration. 
Subsequently, the formulation was analyzed for size and 
drug content as described above.
Cell culture
Cells were grown in humidified atmosphere of 5% CO2 at 
37°C, with media changed every 3–4 days. Caco-2 cells were 
maintained in Eagle’s minimal essential medium (EMEM) 
supplemented with 20% fetal bovine serum (FBS), 2 mM 
L-glutamine, and 100 units/mL penicillin and 100 µg/mL 
streptomycin. Stock cultures were grown in T-75 flasks. Upon 
80%–90% confluency, cells were spilt using 2.5% trypsin 
containing 1.0 mM EDTA. All cell culture media and reagents 
were obtained from Gibco. A549 and MDA-MB-231 cells 
were maintained in RPMI1640 medium supplemented with 
10% FBS, 2 mM L-glutamine, and 100 units/mL penicillin 
and 100 µg/mL streptomycin. Upon 80%–90% confluency, 
cells were spilt using 0.25% trypsin.
Accumulation of nanomicelles  
in Caco-2 cells
Caco-2 cells were seeded in 4-well Lab-tek chamber glass 
slides from Nalgene Nunc Inc (Naperville, IL) at a density 
of 7.2 × 104 cells/well and cultured for 21 days.
Subsequently, FITC-labeled nanomicelles were added 
to the cells and incubated for the specified duration at 
37°C. After incubation, cells were washed three times with 
ice-cold PBS before viewing under a Carl Zeiss fluores-
cence confocal microscope (Oberkochen, Germany) using 
40× objective.
MTT viability assay and lactose  
dehydrogenase (LDh) release assay
The plating densities for A549 cells, MDA-MB-231 cells, 
and Caco-2 cells were 5.0 × 103 cells/well, 3.0 × 103 cells/
well, and 1.33 × 104 cells/well, respectively, in the 96-well 
plates. A549 and MDA-MB-231 cells were incubated for 
24 hours to allow attachment to plate before   experimentation, 
while Caco-2 cells were incubated for 21 days to allow 
  differentiation and tight junction formation. The medium was 
aspirated and replaced with serum-supplemented medium 
containing serial dilutions of quercetin in free (dissolved in 
ethanol) or nanomicellar form.
For MTT viability assay, the cells were treated at 37°C 
for the specified duration, and at the end, MTT was added to 
each well after medium removal and PBS rinsing to remove 
residual drug. Following a 4-hour incubation at 37°C, the well 
content was aspirated and 150 µL DMSO was added to dis-
solve formazan crystals. Absorbance at 570 nm was measured 
with a Tecan SpectraFluorPlus reader (Tecan, Mannedorf, 
Switzerland). Cell viability was calculated as follows:
 
Viability
AbsA bs
AbsA bs
test background
vehicleb ackground
(%) =
−
−
× ×100%
where Abstest, Absbackground, Absvehicle represent the absorbance 
readings from the quercetin-treated wells, the medium-only 
wells, and the vehicle control wells, respectively.
For LDH release assay, treatment groups, and conditions 
were similar to those for MTT viability assay, except that 
the culture medium was collected at the end of treatment for 
LDH detection using Cytotox-One Homogenous Membrane 
Integrity Assay Kit (Promega Corporation, Fitchburg, WI) 
following the manufacturer’s instructions. Fluorescence was 
measured using the Tecan SpectraFluorPlus plate reader with 
an excitation wavelength of 560 nm and   emission wavelength 
of 590 nm. Cytotoxicity was calculated as follow:
 
Cytotoxicity
FF
FF
test background
triton-Xb ackground
(%) =
−
−
×100% %
where Ftest, Ftriton-X and Fbackground represent the fluorescence 
readings from the test condition (CNM or vehicle alone), 
triton-X 0.2%, and background.
Transepithelial electrical resistance 
(TEEr) measurement in Caco-2 cells
Cells were seeded at a density of 1.2 × 104 cells/well in 
  collagen-coated filter membrane polycarbonate transwell 
inserts (12 mm, 1-µm pore size, 0.3 cm2 growth area) obtained 
from BD Biocoat (Erembodegem, Belgium) and incubated 
at 37°C for 21 days. On day 21, the baseline TEER values of 
Caco-2 cells were measured using Millicell ERS-2 Epithelial 
Volt-Ohm Meter, and inserts that record . 600 Ωcm2 were 
used for experiments. The chamber was washed twice with 
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Hank’s balanced salt solution before the addition of drug 
treatment. The cells were treated for 24 hours at 37°C, and 
TEER values were recorded every 24 hours over the study 
duration of 96 hours.
Animal efficacy study
The animal study was conducted in the facilities of the British 
Columbia Cancer Research Center, with methodologies 
approved by the Institutional Animal Care Committee of the 
University of British Columbia, Vancouver, BC, Canada. 
The mice were cared for and used in accordance with the 
Canadian Council on Animal Care Guidelines. All mice used 
were between 20–22 g, and were housed in micro-isolator 
cages and given free access to food and water. Tumors were 
established in female Rag-2M mice by a single subcutaneous 
injection of 5 × 106 A549 cells (in 50 µL) in the lower back area. 
Tumor growth was monitored by caliper measurements along 
the length and width. Tumor volumes were calculated by the 
following formula: Tumor volume = 0.5 × (length × width2). 
When the tumor size reached 50–100 mm3 (3 weeks post-tumor 
cell inoculation), mice were randomized into three study groups 
of six animals per group: (1) untreated control, (2) peroral 
quercetin suspension (vehicle = 25% v/v ethanol in water), 
and (3) peroral nanomicellar quercetin. The dose of quercetin 
was 30 mg/kg, following a schedule of three times per week 
(Monday/Wednesday/Friday) for 3 weeks. Tumor size and 
body weight of the mice was monitored thrice weekly. Animals 
whose tumor size reached 1000 mm3, developed ulcerations, or 
displayed a weight loss of more than 5% were euthanized.
Statistics
Where appropriate, results are expressed as mean ± SEM of at 
least three independent experiments. Statistical significance 
was assessed using one-way ANOVA followed by Fisher’s 
least significant difference (LSD) test for multiple compari-
sons. A P value of ,0.05 was considered to be statistically 
significant. All statistical analyses were carried out using 
SPSS software (v 19.0; IBM, Armonk, NY).
Results
Formulating quercetin into PEG-lipid  
nanomicelles
The commonly used PEG-lipid conjugate, DSPE-PEG2000, 
was combined with quercetin in various weight proportions 
(1%–5% w/w of quercetin in DSPE-PEG2000). As shown in 
Table 1, the incorporation efficiencies of quercetin into the 
DSPE-PEG2000 nanomicelles were found to be 88.9% and above 
when the content of quercetin was up to 4% w/w. At 5% w/w, 
the incorporation efficiency was reduced to 79.3%. The size 
of the drug-loaded nanomicelles ranged from 15.4 to 18.5 nm 
(Table 1), and the polydispersity indices were ,0.250 for 
all the nanomicellar formulations. The zeta potentials of the 
empty and drug-loaded nanomicelles were −11.8 ± 0.7 mV 
and −14.8 ± 0.7 mV , respectively. The highest concentration 
of nanomicellar quercetin in Hepes-buffered saline that 
could be achieved without precipitation was 3 mg/mL. This 
represents a 110-fold increase in the aqueous concentration of 
quercetin, calculated based on the aqueous solubility of free 
quercetin of 80 µM.17,18 Furthermore, nanomicellar quercetin 
could be processed into a powder by freeze-drying, without 
the need of a cryoprotectant or lyoprotectant. Reconstitution 
of the freeze-dried, nanomicellar quercetin with water did not 
result in a change in size or quercetin content (data not shown). 
Hence, subsequent evaluation of the nanomicellar formulation 
was based on the reconstituted nanomicellar quercetin.
In vitro cytotoxicity of nanomicellar 
quercetin in the A549 lung cancer cell line
The cytotoxicity of nanomicellar quercetin was evalu-
ated in the A549 human lung cancer cell line. The highest 
concentration of quercetin evaluated was 100 µM, as drug 
precipitation was observed at higher drug concentrations. 
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Figure 1 MTT viability of free () and nanomicellar () quercetin in A549 human 
lung cancer cell line upon 72 hours of exposure.
Table 1 Formulation attributes of nanomicellar quercetin
Quercetin (% w/w) Incorporation efficiency (%) Size (nm)
1 94.5 ± 7.0 17.9 ± 2.0
2 93.1 ± 3.6 18.5 ± 1.4
3 92.2 ± 4.3 17.6 ± 0.9
4 88.9 ± 5.6 17.7 ± 0.8
5 79.3 ± 13.3 15.4 ± 1.4
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As shown in Figure 1, the anticancer activity of quercetin 
could be   significantly improved over the free drug through 
the   nanomicellar formulation, as determined by the MTT 
viability assay. Of note, non-drug loaded DSPE-PEG2000 
nanomicelles did not cause significant toxicity to the A549 
lung cancer cells up to a concentration of 1 mM, with cell 
viability of .85%. To ensure that the cytotoxic effect was 
not cell line specific, the MDA-MB-231 human breast cancer 
cell line was treated with free and nanomicellar quercetin. 
As shown in Suppl Data Figure 1, a similar trend could be 
observed whereby the activity of quercetin could be signifi-
cantly increased when formulated into the nanomicelles.
Stability of nanomicellar quercetin  
in simulated physiological fluids
Since the nanomicelles are to be administered perorally, stability 
in the fluids of the gastrointestinal tract has to be demonstrated. 
The stability of nanomicellar quercetin was evaluated over time 
in simulated gastric fluid (SGF, 0.2% w/v NaCl in 0.7% v/v HCl, 
pH 1.2) and simulated intestinal fluid (SIF, 0.05 M potassium 
dihydrogen phosphate/0.02 M sodium hydroxide, pH 7.0). 
The quercetin nanomicelles were found to be stable, without 
significant change in size or drug precipitation (Figure 2). To 
investigate the amount of quercetin retained in the nanomicelles, 
the micelle samples were dialyzed against 1:5000 (v/v) SGF or 
SIF at 37°C using dialysis cassettes. Approximately 70%–75% 
of incorporated quercetin was retained in the nanomicelles in 
the respective simulated fluids (Figure 2).
Interaction of nanomicellar quercetin 
with Caco-2 cell monolayer
The well-established Caco-2 cell monolayer was employed 
as the in vitro model for gastrointestinal epithelium, and the 
cellular accumulation of the PEG-lipid nanomicelles was 
assessed by confocal microscopy. To facilitate visualization, 
the nanomicelles were spiked with 1 mol% DSPE-PEG2000-
N-carboxyfluorescein. The Caco-2 cells were exposed to the 
fluorescence-labeled nanomicelles for up to 24 hours at 37°C, 
and cellular accumulation of the nanomicelles increased 
over time (Figure 3A). Furthermore, the accumulation of 
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Figure 2 Stability of quercetin nanomicelles in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF).
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the nanomicelles was independent of P-gp activity and 
endocytic processes, which was supported by results sum-
marized in Suppl Data Figure 2. Cellular accumulation of 
the carboxyfluorescein-tagged nanomicelles occurred even 
in the presence of the P-gp inhibitor cyclosporine A or in the 
presence of endocytic inhibitors (hyperosmotic sucrose of 
0.45 M or Brefeldin A) or a change of incubation temperature 
from 37°C to 4°C. Collectively, these data suggest that the 
nanomicelles are likely to accumulate inside Caco-2 cells 
by passive diffusion.
One possible route to facilitate drug absorption through 
the intestinal epithelium is by disrupting the tight junctions 
and thus making paracellular transport of drug molecules 
possible, which could be reflected by a decrease in the 
TEER.19 Nevertheless, it is also of equal importance that the 
disruption of the epithelial tight junctions is only transient, 
as irreversible disruption could represent potential toxicity 
to the intestinal epithelium. As such, differentiated Caco-2 
cell monolayers grown in transwell inserts were exposed to 
free or nanomicellar quercetin for 24 hours, and TEER mea-
surements were carried out over a time course of 96 hours. 
As shown in Figure 3B, Caco-2 cell monolayer treated with 
free quercetin had small yet statistically   significant increase 
in TEER after 48 hours of exposure that gradually decreased 
back to control level (t = 0 hours). This observation is in 
line with the protective effect of quercetin on the intestinal 
barrier function, which acts by promoting the assembly 
and expression of tight junction proteins.20 In contrast, 
significant reduction in TEER was observed in Caco-2 
cell monolayer treated with nanomicellar quercetin during 
the first 48 hours. Of note, the reduction in TEER in the 
nanomicellar   quercetin treatment group could be gradually 
increased back to control level (t = 0 hours), indicating the 
reversibility of the treatment.
To further investigate the potential toxicity of the nano-
micellar quercetin formulation, release of LDH was deter-
mined in differentiated Caco-2 cell monolayer upon 24-hour 
treatment with free or nanomicellar quercetin (Figure 4). 
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Figure  4  LDh  cytotoxicity  in  Caco-2  cells  when  treated  with  free  ()  and 
nanomicellar () quercetin for 24 hours.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
656
Tan et alInternational Journal of Nanomedicine 2012:7
Treatment with free quercetin was non-toxic over the con-
centration range tested, with ∼10% LDH released relative 
to triton-X control. In contrast, nanomicellar quercetin 
treatment yielded a small but significant increase in LDH 
release of ∼25% relative to triton-X control. Empty, non-
drug loaded nanomicelles were evaluated at concentrations 
up to 1 mM and were found to be relatively non-toxic to 
the Caco-2 cell monolayer, with viability of ∼80% at 1 mM 
(Suppl Data, Figure 3).
In vivo efficacy of nanomicellar  
quercetin in human A549 lung  
tumor xenograft model
Based on the in vitro evaluation of the nanomicellar quercetin 
formulation which provided promising results, the biological 
activity of the peroral formulation was further investigated 
in the A549 lung tumor xenograft model. Quercetin was 
administered to the tumor-bearing mice via oral gavage 
either in the nanomicellar form or in a 25% v/v ethanol-based 
suspension, with a dose of 30 mg/kg following a schedule 
of three times per week (Monday/Wednesday/Friday) for 
3 weeks. The results demonstrated that the anti-tumor activity 
of quercetin was significantly increased when administered 
as the peroral nanomicelles compared to control and peroral 
quercetin suspension (Figure 5A). Specifically, tumor growth 
inhibition at 10-week post-tumor inoculation was 83% for 
peroral quercetin suspension and 48% for peroral nanomicel-
lar formulation. The two quercetin formulations were well 
tolerated by the animals, as reflected by minimal changes in 
the body weight of the mice (Figure 5B). No unusual obser-
vations were made upon necropsies of the animals from all 
three study groups.
Discussion
Quercetin, a flavanol that is found in certain vegetables, 
fruits, and tea, has been shown to have a range of biochemi-
cal and biological activities that could have the potential to 
translate to therapeutic benefits. In addition to its antioxidant 
and anti-inflammatory effects, quercetin as a tyrosine kinase 
inhibitor8 is able to modulate multiple signaling pathways that 
would have considerable implications in the therapeutic and 
prophylactic values for diseases such as cancer. However, 
realizing the biological benefits of quercetin in the clinical 
setting is mostly hampered by its low water solubility and 
poor absorption into the body. For instance, the baseline 
plasma concentration of quercetin from dietary intake is 
50–80 nM,21 and even with supplementation at 1 g/day for 
28 days, the plasma concentration is ∼1.5 µM,22 which is 
far below the concentration that is necessary to bring about 
the intended pharmacological effects of quercetin (such as 
the concentrations needed for anticancer effect presented 
in Figure 1). Thus, it is imperative to develop appropriate 
vehicles for quercetin, and it is the intention of our current 
study to develop a peroral nanomicellar system that could 
potentially improve its anticancer activity, which has not 
been extensively studied.
Since the quercetin-loaded DSPE-PEG2000 nanomicelles 
are intended for peroral application, the nanomicelles should 
be able to withstand the harsh environment of the digestive 
tract such as the drastic changes in pH, and at the same time, 
be relatively non-toxic to the intestinal epithelium. As demon-
strated in Figure 2, the quercetin nanomicelles were relatively 
stable at pH 1.2 and pH 7, with no significant changes in size 
and ∼30% release of quercetin. These findings are in good 
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Figure 5 In vivo efficacy of orally given quercetin nanomicelles in subcutaneous 
A549 lung tumor xenograft murine model. Mice (n = 6) were treated with 30 mg/kg 
quercetin three times per week for 3 weeks by oral gavage, with treatment given in 
3, 4, and 5 weeks post tumor inoculation. Study groups included untreated control 
(), quercetin in ethanol-based suspension () or nanomicelles ().
Notes: *represents P , 0.05 compared to control and quercetin oral suspension.
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agreement with a previous study by Dabholkar et al which 
reported no significant change in the size of mixed micelles 
made of DSPE-PEG2000 and D-α-tocopheryl polyethylene 
glycol 1000 succinate (TPGS) incubated in acidic (pH 1.2) 
and neutral (pH 7.4) conditions.23 In terms of toxicity to the 
intestinal epithelium, although the incorporation of quercetin 
into the nanomicelles has slightly increased the cytotoxicity, 
as reflected by the data in Figure 4, this level of cytotoxicity 
(∼25% as determined by LDH release) was comparable to 
those reported for TPGS and its analogs which are PEG-
derivatives well established for their ability to modulate 
peroral drug absorption. The Caco-2 cytotoxicity of the TPGS 
analogs was reported to range from 20%–40%, as determined 
by LDH release.24 Furthermore, quercetin-loaded nanomi-
celles did not induce irreversible reduction in the TEER of 
the Caco-2 epithelium (Figure 3B). This finding, together 
with those in Figure 4 and Suppl Data Figure 3, showed that 
the quercetin-loaded nanomicelles were relatively non-toxic, 
which is in line with another study reporting that empty or 
meso-tetraphenyl porphine loaded DSPE-PEG2000 micelles 
were minimally toxic to Caco-2 cells.25
The therapeutic benefits of perorally administered 
quercetin is limited by poor absorption into the body that 
could be attributed to a number of reasons, including its 
chemical structure, low water solubility, and extensive 
metabolism and degradation in the gastrointestinal tract.26 Of 
interest, quercetin has been shown to protect the intestinal 
epithelial barrier function by promoting the expression of 
a number of tight junction proteins and increase TEER 
of Caco-2 monolayer,27 implying that quercetin may limit 
its own absorption into the body by reducing paracellular 
permeability. Our current DSPE-PEG2000-based peroral 
nanomicellar formulation could increase the anticancer 
activity of quercetin by two possible mechanisms with 
supportive data: (1) increase in the aqueous concentration of 
quercetin (by 110-fold to 3 mg/mL) through solubilization in 
the nanomicelles, and (2) increase in permeability through 
modulation of the epithelial tight junctions as reflected by the 
transient decrease in TEER. At the molecular level, quercetin 
is able to increase the distribution of tight junction proteins, 
ZO-2, occludin, and claudin-1, to the actin cytoskeleton 
fraction, as well as increase the expression of claudin-4 in 
cytoskeleton fraction and in whole cell.27 From Figure 3B, 
it can be seen that empty nanomicelles could reduce TEER 
reversibly, and it is possible that the empty micelles could 
disrupt the assembly of the tight junction complex through the 
partition of DSPE-PEG2000 into the cell membrane bilayer.
Nevertheless, other possible mechanisms that could 
contribute to the increased activity of quercetin by the nano-
micellar peroral formulation could not be ruled out. One 
such mechanism is the potential ability of the nanomicelles 
to protect quercetin from the enzymatic and degradative 
action in the intestinal tract. The metabolism of quercetin is 
complex, involving the formation of multiple metabolites by 
different pathways.28 Thus, future investigations on the full 
pharmacokinetic behavior of the nanomicellar formulation 
with metabolite profiling are necessary to gain insights if the 
nanomicelles could indeed protect quercetin from enzymatic 
metabolism in vivo. Currently, we are establishing mass 
spectroscopy-based analytical method to characterize the 
metabonomics of quercetin to address the question. Another 
possible mechanism is the increased mucoadhesion of the 
nanomicelles to the intestinal mucosa that could be provided 
by the PEG shell of the nanomicelles.29 Furthermore, it has 
been suggested that nanovehicles made of lipids could be 
taken up by lymphoid tissues in the intestinal tract which in 
turn could circumvent first pass metabolism.13
It is encouraging that the nanomicellar peroral formula-
tion could enhance the anticancer activity of quercetin at a 
dose of 30 mg/kg. It has been reported that a dose of 3 g/kg, 
which is 100-fold higher than ours, did not cause any toxic 
or harmful effect to mice.30 Thus, future studies could titrate 
our current dose to higher levels, with the dosing frequency 
adjusted to daily dosing. The dose titration study could be 
further coupled to the examination of the correlation between 
tyrosine kinase inhibition and tumor growth inhibition, 
which could yield interesting pharmacodynamic data on 
this nanomicellar peroral formulation. Further evaluation 
could also include the potential of this nanomicellar peroral 
formulation as a chemotherapeutic and chemopreventive 
agent in animal models.
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Figure S1 MTT viability of free and nanomicellar quercetin in MDA-MB-231 human breast cancer cell line upon 72 hours of exposure. The concentrations of empty micelle 
were 96 µM and 192 µM for 30 µM and 60 µM nanomicellar quercetin, respectively.
Notes: Data represent mean ± SEM from three independent experiments. *P , 0.05 as compared to free quercetin group.
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Figure S2 Cellular accumulation of FITC-labeled nanomicelles over 24 hours of incubation under various conditions: (A) at 4°C, (B) at 37°C, (C) without cyclosporine A, 
(D) with cyclosporine A, (E) without 0.45 M sucrose, (F) with 0.45 M sucrose, (G) without brefeldine A, (H) with brefeldine A. 
Notes: representative images from three independent studies are shown.
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Figure S3 MTT viability of (A) empty, non-drug loaded nanomicelles, (B) quercetin-loaded nanomicelles (showing micelle concentrations), and (C) free quercetin in Caco-2 
cell monolayer upon 24 h of exposure.
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